Skip to main content

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Publication ,  Journal Article
Fowler, VG; Boucher, HW; Corey, GR; Abrutyn, E; Karchmer, AW; Rupp, ME; Levine, DP; Chambers, HF; Tally, FP; Vigliani, GA; Cabell, CH; Cook, P ...
Published in: N Engl J Med
August 17, 2006

BACKGROUND: Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. METHODS: We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight daily and 122 to receive initial low-dose gentamicin plus either an antistaphylococcal penicillin or vancomycin. The primary efficacy end point was treatment success 42 days after the end of therapy. RESULTS: Forty-two days after the end of therapy in the modified intention-to-treat analysis, a successful outcome was documented for 53 of 120 patients who received daptomycin as compared with 48 of 115 patients who received standard therapy (44.2 percent vs. 41.7 percent; absolute difference, 2.4 percent; 95 percent confidence interval, -10.2 to 15.1 percent). Our results met prespecified criteria for the noninferiority of daptomycin. The success rates were similar in subgroups of patients with complicated bacteremia, right-sided endocarditis, and methicillin-resistant S. aureus. Daptomycin therapy was associated with a higher rate of microbiologic failure than was standard therapy (19 vs. 11 patients, P=0.17). In 6 of the 19 patients with microbiologic failure in the daptomycin group, isolates with reduced susceptibility to daptomycin emerged; similarly, a reduced susceptibility to vancomycin was noted in isolates from patients treated with vancomycin. As compared with daptomycin therapy, standard therapy was associated with a nonsignificantly higher rate of adverse events that led to treatment failure due to the discontinuation of therapy (17 vs. 8, P=0.06). Clinically significant renal dysfunction occurred in 11.0 percent of patients who received daptomycin and in 26.3 percent of patients who received standard therapy (P=0.004). CONCLUSIONS: Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis. (ClinicalTrials.gov number, NCT00093067 [ClinicalTrials.gov].).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

August 17, 2006

Volume

355

Issue

7

Start / End Page

653 / 665

Location

United States

Related Subject Headings

  • Vancomycin
  • Treatment Outcome
  • Staphylococcus aureus
  • Staphylococcal Infections
  • Penicillins
  • Middle Aged
  • Methicillin Resistance
  • Male
  • Humans
  • Gentamicins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., … S. aureus Endocarditis and Bacteremia Study Group, . (2006). Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med, 355(7), 653–665. https://doi.org/10.1056/NEJMoa053783
Fowler, Vance G., Helen W. Boucher, G Ralph Corey, Elias Abrutyn, Adolf W. Karchmer, Mark E. Rupp, Donald P. Levine, et al. “Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.N Engl J Med 355, no. 7 (August 17, 2006): 653–65. https://doi.org/10.1056/NEJMoa053783.
Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653–65.
Fowler, Vance G., et al. “Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.N Engl J Med, vol. 355, no. 7, Aug. 2006, pp. 653–65. Pubmed, doi:10.1056/NEJMoa053783.
Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006 Aug 17;355(7):653–665.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

August 17, 2006

Volume

355

Issue

7

Start / End Page

653 / 665

Location

United States

Related Subject Headings

  • Vancomycin
  • Treatment Outcome
  • Staphylococcus aureus
  • Staphylococcal Infections
  • Penicillins
  • Middle Aged
  • Methicillin Resistance
  • Male
  • Humans
  • Gentamicins